Primary, Pulmonary Providers Endorse Lung CA Screening

This article originally appeared here.
Share this content:
Primary, Pulmonary Providers Endorse Lung CA Screening
Primary, Pulmonary Providers Endorse Lung CA Screening

THURSDAY, Oct. 12, 2017 (HealthDay News) -- Primary care clinicians and pulmonologists endorse lung cancer screening (LCS), but there are limitations in their knowledge of screening components, according to a study published online Sept. 21 in the Annals of the American Thoracic Society.

Matthew Triplette, M.D., M.P.H., from the University of Washington in Seattle, and colleagues conducted an electronic survey of primary care and pulmonary providers to examine knowledge, beliefs, attitudes, barriers, and facilitators related to LCS. There were 196 participants; 80 percent of them were primary care clinicians, 19 percent were pulmonologists, and 1 percent were others.

The researchers found that 74 percent of participants endorsed the effectiveness of LCS; performance was suboptimal on knowledge-based assessments of screening eligibility, documentation, and nodule management. Key barriers included inadequate time and staffing (both 36 percent), and not addressing screening because patients had too many other illnesses (38 percent). Decision aids, used at the point-of-referral, were important clinical facilitators of LCS (51 percent) and facilitators of provider knowledge (59 percent). Several differences were seen by provider specialty, including primary care clinicians more often reporting time constraints and their patients having too many other illnesses to address screening.

"Providers endorsed the benefits of LCS, but there are limitations in provider knowledge of key screening components," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Jury Awards 4.62B in Johnson  Johnson Talcum Powder Lawsuit

Jury Awards $4.62B in Johnson & Johnson Talcum ...

The award includes $550 million in compensatory damages and $4.14 billion in punitive damages

100 Now Sickened by Salmonella-Tainted Honey Smacks Cereal

100 Now Sickened by Salmonella-Tainted Honey Smacks Cereal

Thirty people have been hospitalized, but no deaths have been reported

Data Support FDA Restrictions on Child Cough and Cold Medicines

Data Support FDA Restrictions on Child Cough and ...

Surveillance data showed more adverse events for children exposed to hydrocodone than codeine

is free, fast, and customized just for you!




Already a member?

Sign In Now »